Shandong Tianming Pharmaceutical, a GMP-certified leader in advanced API and intermediate manufacturing, will unveil its latest innovations at CPHI China 2025 (June 24-26, Shanghai New International Expo Centre).
Visit us at Booth W2G30 to explore cutting-edge solutions reshaping pharmaceutical synthesis.
As an eight-time exhibitor with proven industry partnerships, we deliver more than products – we offer actionable pathways to:
1/Explore cutting-edge API synthesis technology and break through R&D bottlenecks
2/Unlock customized solutions:
3/Overcome Regulatory Hurdles
4/Global compliance escort, opening up international market access channels
– GLP-1 Agonist Intermediates: >99.9% chiral purity for obesity/diabetes pipelines
– Antibiotic Resistance Fighters: β-lactamase inhibitor scaffolds with 80% oral bioavailability
– On-Demand Synthesis: From R&D samples to commercial batches
With 300+ commercial APIs and 15 years of GMP excellence, Tianming enables partners across 40 countries to overcome synthesis scalability, compliance, and sustainability challenges.
We look forward to seeing you at CPHI China 2025!
Best regards
Sales Team
Shandong Tianming Pharmaceutical Group
As a leading API/intermediate manufacturer, we showcase advanced synthesis tech and regulatory-ready solutions at CPHI 2025. Booth No.: W2G30
Expert analysis of API synthesis complexities: route selection trade-offs, scale-up challenges, impurity control tactics, and green chemistry innovations. Includes industrial case studies on yield optimization and troubleshooting.
This guide reveals why your Pharmaceutical Ingredient List is vital for compliance and innovation. Learn sourcing strategies, quality benchmarks, and 2024 API trend（Attached API list）
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.